Participated · Series B · Apr 2026

Patlytics offers an end-to-end AI platform purpose-built for patent workflows, covering invention harvesting, application drafting, infringement analysis, invalidity contentions, and portfolio management. The company reports measurable customer impacts such as an 80% reduction in project time, more than $30,000 saved per claim chart, and up to 15 hours recovered per patent application. Patlytics is trusted by over 40% of Am Law 100 firms and a number of corporate IP teams and ranked practices. Following the $40 million Series B, bringing total funding to about $65 million, the company plans to develop an AI-native collaboration suite, domain-specific autonomous AI Agents, and deeper chem-bio capabilities. Patlytics is expanding globally with a new London office and a recently appointed Head of EMEA. The company is headquartered in New York.

Participated · Seed · Mar 2026

Advocacy offers a context-driven platform that captures, organizes, and applies matter-critical information for litigators, moving work from isolated point solutions to a unified, memory-based workspace. Its technology ingests evidence—including documents, audio, and video—and continuously maps it to a centralized case timeline, boosting accuracy for research, drafting, analysis, and strategy. Built by experienced litigators, the system aims to eliminate the risk of AI hallucinations by preserving deep, matter-specific context throughout a case’s lifecycle. The product is already in use with paying clients and is running pilots at top-tier plaintiff and defense firms, including Am Law 100 practices. Recent updates extend the proprietary memory layer across every surface where litigation work occurs, enabling seamless context orchestration. With fresh capital, the company plans to grow its product and engineering teams, hire legal alignment experts, and deepen partnerships such as its ongoing collaboration with e-discovery leader Relativity. Though revenue figures have not been disclosed, Advocacy reports accelerating demand among large law firms and specialized boutiques.

Participated · Seed · Dec 2017

Heretik, founded in 2016 by CEO Charlie Connor, provides a contract review solution that uses machine learning to help attorneys identify risks, obligations, and opportunities in contracts. The company operates on the Relativity platform and integrates its product there. Heretik completed $2.4M in seed financing to support growth. The company intends to use the funds to expand its sales, marketing, and customer success teams and to support key international partnerships. It also plans to accelerate its product offering through the Relativity platform. Investors in the round included Corazon Capital, Chicago Ventures, and Relativity.

Participated · Series B · Sep 2016

TenNor Therapeutics is a clinical-stage company in Suzhou, China, focused on discovery and development of differentiated new drug products against bacterial infection and metabolism-related diseases. It possesses a multi-targeting drug conjugate technology platform and strong new drug development portfolio with global IP protection. Several products are currently in late-stage clinical development targeting H. pylori infection, medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company raised over RMB300M in a Series E financing; backers included AMR Action Fund, Zhongshan Venture Capital and other existing investors. Proceeds will support development and the pursuit of regulatory approval in China for rifasutenizol, which could become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years. Led by founder and CEO Dr. Zhenkun Ma, TenNor says it is committed to addressing unmet needs and providing safe, effective therapies for patients in China and globally. TenNor Therapeutics is a Suzhou, China–based clinical-stage company focused on developing dual-acting antibiotics. Its lead candidate is TNP-2092, an oral capsule designed as a locally acting gastrointestinal antibiotic with potential to improve treatment of Helicobacter pylori and other gastrointestinal bacterial infections. The compound is currently in early-stage clinical development. TenNor intends to use the Series B proceeds to advance TNP-2092 into Phase III trials, move a second product to clinical proof-of-concept, and advance a third into Phase I. Founded in 2013 in BioBAY by Dr. Zhenkun Ma, the company is advancing several dual-acting molecules through preclinical and clinical stages. TenNor has acquired patents and other assets from Cumbre IP Venture and patents from the TB Alliance and raised $25M in this Series B.